Literature DB >> 1637792

Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association.

D L Hahn1, R Golubjatnikov.   

Abstract

Two recent studies, which did not adequately control for smoking status, found associations between Chlamydia pneumoniae serological titers and various manifestations of coronary artery disease (CAD). The validity of C. pneumoniae-CAD associations found in case-control studies has been criticized on the basis that smoking, known to be associated with CAD and hypothesized to be associated with C. pneumoniae seroreactivity via an increased prevalence of respiratory infection in smokers, could be an uncontrolled confounder in these studies. We investigated associations between current smoking status and C. pneumoniae serological titers in a cohort of 365 outpatients (mean age, 34 years) with respiratory illness. Current smokers were significantly (p = 0.04) more likely than nonsmokers to have C. pneumoniae titers greater than or equal to 1:128, and there was a significant (p less than 0.05) "dose-response" association between titer category and smoking, which persisted after controlling for age and sex in a logistic-regression model. These results support the hypothesis that smoking may be a confounder of the association of C. pneumoniae antibody titer and smoking-associated diseases such as CAD. Future studies into these associations should control for cigarette use.

Entities:  

Mesh:

Year:  1992        PMID: 1637792     DOI: 10.1161/01.atv.12.8.945

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  10 in total

1.  Circulating nucleic acids of Chlamydia pneumoniae and cytomegalovirus in patients undergoing coronary angiography.

Authors:  M Smieja; S Chong; M Natarajan; A Petrich; L Rainen; J B Mahony
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

2.  Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study.

Authors:  D P Strachan; D Carrington; M A Mendall; L Ballam; J Morris; B K Butland; P M Sweetnam; P C Elwood
Journal:  BMJ       Date:  1999-04-17

3.  Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis.

Authors:  W Stille; R Dittmann; G Just-Nübling
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

4.  Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma.

Authors:  D L Hahn; T Anttila; P Saikku
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

Review 5.  [Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection].

Authors:  W Stille; R Dittmann
Journal:  Herz       Date:  1998-05       Impact factor: 1.443

6.  Chlamydia pneumoniae and asthma.

Authors:  P J Cook; P Davies; W Tunnicliffe; J G Ayres; D Honeybourne; R Wise
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

7.  High prevalence of antibodies to Chlamydia pneumoniae; determinants of IgG and IgA seropositivity among Jerusalem residents.

Authors:  O Paltiel; J D Kark; M Leinonen; P Saikku
Journal:  Epidemiol Infect       Date:  1995-06       Impact factor: 2.451

8.  Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern.

Authors:  Hem C Jha; Harsh Vardhan; Rishein Gupta; Rakesh Varma; Jagdish Prasad; Aruna Mittal
Journal:  BMC Infect Dis       Date:  2007-05-30       Impact factor: 3.090

9.  Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review.

Authors:  Marek Smieja; James Mahony; Astrid Petrich; Jens Boman; Max Chernesky
Journal:  BMC Infect Dis       Date:  2002-10-01       Impact factor: 3.090

10.  Smoking, season, and detection of Chlamydia pneumoniae DNA in clinically stable COPD patients.

Authors:  Marek Smieja; Richard Leigh; Astrid Petrich; Sylvia Chong; Dennis Kamada; Frederick E Hargreave; Charles H Goldsmith; Max Chernesky; James B Mahony
Journal:  BMC Infect Dis       Date:  2002-07-05       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.